4 billion injections of large varieties! The Guangdong pharmaceutical company 2.4 new drugs were approved for clinical treatment.

On July 16, Jincheng Pharmaceuticals announced that it had received a notice from the holding subsidiary Of Guangdong Jincheng Jinjin, which obtained the approval of the State Drug Administration to issue the "Notice of Approval of Drug Clinical Trials" on the 2.4-type modified new drug for injection sodium cephalosporin, which will carry out clinical trials of new indications.
-meter net data show that in 2019 China's public medical institutions terminal cephalosporine sales of 4.125 billion yuan.
the basic condition of the drug Cefazolin Sodium is the first generation of cephalosporins, antibacterial spectrum, has been approved for the treatment of sensitive bacteria caused by respiratory infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, septicaemia, infectious endocarditis, liver and bile system infections, reproductive system infections and perioperative prevention of infections. According to
-minnet data, sales of cephalosporine in terminals in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as Public Medical Institutions in China) in 2019 were 4.125 billion yuan, up 2.14% year-on-year.
, Shenzhen China Resources nine new accounted for 80.56 percent of the market share, Shenzhen Lijian Pharmaceuticals accounted for 7.71 percent, Guangdong Jincheng Jinsu accounted for 3.33 percent.
China's public medical institutions terminal cephalosporine sales (units: 10,000 yuan) the current domestic market cephalosporine products are injected with cephalosporine sodium, injection with sodium cephalosporinin, injection of cephalosporine sodium / sodium chloride injection, injection with cephalosporine sodium manufacturers as many as 74, the competition is very fierce.
the competitive pattern of cephalosporine jinjin has been approved for production in 3 product regulations, the declared injection of cephalosporine sodium in line with the registration requirements of 2.4 types of improved new drugs.
inquiries, at home and abroad have not been approved with the same product "jaw facial gap infection" indications, the global new indications.
source: Minnet database, public company announcement.